ArticleClinical, cosmetic and investigational dermatology2026
JAK Activation Drives MED15-Associated Melanocyte Dysfunction in Vitiligo Beyond Immune Cells.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vitiligo is an autoimmune disorder characterized by selective melanocyte loss, largely driven by interferon-gamma (IFN-γ)-induced Janus kinase/signal transducers and activators of transcription (JAK-STAT) activation. While the immune aspects of JAK-STAT signaling are well-documented, its downstream transcriptional mediators within melanocytes remain incompletely understood. Methods: We integrated multi-omics analyses, including cross-tissue and single-tissue transcriptome-wide association studies (TWAS), conditional and joint analysis (COJO), and summary data-based Mendelian randomization (SMR), using genome-wide association study (GWAS) data comprising 391 vitiligo cases and 465,673 controls. These were combined with single-cell RNA sequencing (scRNA-seq) data from 15 samples (10 vitiligo lesions and 5 healthy controls) and in vitro functional assays to identify causal JAK-responsive genes associated with vitiligo. Results: Mediator complex subunit 15 (MED15) emerged as a robust gene associated with increased vitiligo risk (significance thresholds were set at P < 0.05, with False Discovery Rate [FDR] corrections detailed in Supplementary Data). Single-cell transcriptomic data revealed significant upregulation of MED15 in melanocytes from lesional skin, positively correlated with STAT1 expression and enrichment of the JAK-STAT pathway. Functional assays confirmed that MED15 overexpression profoundly inhibited melanocyte proliferation and suppressed intrinsic melanin synthesis, both of which were significantly reversed by JAK inhibition with Ruxolitinib. Furthermore, dual-luciferase reporter assays confirmed that MED15 is a direct transcriptional target of STAT1, governed by upstream JAK signaling. Conclusion: MED15 functions as a JAK-responsive transcriptional cofactor contributing to melanocyte proliferation and melanogenesis dysfunction in vitiligo. These findings establish a direct STAT1-MED15 transcriptional axis driving melanocyte injury, offering new insights into transcriptional mechanisms and potential therapeutic targets. MED15 may represent a complementary therapeutic target alongside JAK inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.